This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

AVROBIO (AVRO) Stock Overview

A clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. More details

AVRO fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	3/6
Financial Health	6/6
Dividends	0/6

Rewards

Price-To-Earnings ratio (24.9x) is below the Biotechs industry average (27.2x)

Became profitable this year

Risk Analysis

Makes less than USD$1m in revenue ($0)

Earnings are forecast to decline by an average of 18.4% per year for the next 3 years

Large one-off items impacting financial results

Does not have a meaningful market cap ($64M)

AVRO Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

AVROBIO, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for AVROBIO
Historical stock prices
Current Share Price	US$16.80
52 Week High	US$19.80
52 Week Low	US$10.56
Beta	1.22
1 Month Change	1.45%
3 Month Change	9.38%
1 Year Change	44.82%
3 Year Change	-85.45%
5 Year Change	-90.89%
Change since IPO	-95.51%

Recent updates

Seeking Alpha • Oct 18

Avrobio rises as gene therapy for Gaucher disease gets ILAP designation in UK

The U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) granted an Innovation Passport under the Innovative Licensing and Access Pathway (ILAP) to Avrobio's (NASDAQ:AVRO) gene therapy AVR-RD-02 to treat Gaucher disease. The Innovation Passport is the first step in the ILAP process for regulatory and development milestones with the aim of early patient access in the U.K., the company said in a statement on Tuesday. Avrobio's noted that AVR-RD-02 has previously received fast track status in the U.S. and orphan drug designations in the U.S. and EU. Gaucher disease is a rare lysosomal disorder caused by buildup of certain fatty substances in organs, mainly the in the spleen and liver. AVRO +8.65% to $0.66 premarket Oct. 18

Seeking Alpha • Sep 20

Avrobio stock rises as kidney disease gene therapy gets FDA rare pediatric disease status

The U.S. Food and Drug Administration (FDA) granted rare pediatric disease designation to Avrobio's (NASDAQ:AVRO) gene therapy AVR-RD-04 to treat cystinosis. Cystinosis is a rare, multisystem genetic disorder characterized by the excess build up of an amino acid called cystine in different tissues and organs, with the most affected being the kidneys, and eyes. This can damage the kidneys and can progress to end-stage kidney disease. AVR-RD-04 is designed to genetically modify patients' own hematopoietic stem cells (HSCs) to express the gene encoding cystinosin, the protein which is deficient in people living with cystinosis, the company said in a Sept. 20 press release. Avrobio added that AVR-RD-04 is the first gene therapy in development for cystinosis. AVRO +6.25% to $0.85 premarket Sept. 20

Seeking Alpha • Jul 13

AVROBIO granted FDA’s orphan drug designation for metabolic disorder therapy

The shares of gene therapy company AVROBIO (NASDAQ:AVRO) jumped ~9% in the pre-market Monday after the company announced that the FDA awarded the orphan drug designation for AVR-RD-05, a gene therapy candidate for mucopolysaccharidosis type II (MPSII), or Hunter syndrome. MPSII belong to a group of inherited metabolic disorders collectively called mucopolysaccharidosis. The rare lysosomal disorder primarily affects young boys. With its orphan drug designation, the FDA aims to offer financial incentives to drug developers targeting rare diseases and conditions. In addition to tax credits for clinical trial costs and waiver of the user fee for marketing applications, the developers of orphan drugs can claim seven years of marketing exclusivity upon regulatory approval of the treatment. In 2023, AVROBIO (AVRO) plans to start a Phase 1/2 clinical trial for Hunter syndrome in collaboration with the University of Manchester, UK.

Analysis Article • Nov 13

Here's Why We're Watching AVROBIO's (NASDAQ:AVRO) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Analysis Article • Aug 10

We're Keeping An Eye On AVROBIO's (NASDAQ:AVRO) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Analysis Article • Mar 08

Here's Why We're Not Too Worried About AVROBIO's (NASDAQ:AVRO) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Analysis Article • Nov 23

We Think AVROBIO (NASDAQ:AVRO) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

	AVRO	US Biotechs	US Market
7D	-4.8%	2.4%	1.1%
1Y	44.8%	34.6%	28.7%

Return vs Industry: AVRO exceeded the US Biotechs industry which returned 6.7% over the past year.

Return vs Market: AVRO exceeded the US Market which returned 23.3% over the past year.

Price Volatility

Is AVRO's price volatile compared to industry and market?
AVRO volatility
AVRO Average Weekly Movement	5.6%
Biotechs Industry Average Movement	10.8%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.4%
10% least volatile stocks in US Market	3.1%

Stable Share Price: AVRO has not had significant price volatility in the past 3 months.

Volatility Over Time: AVRO's weekly volatility (6%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2015	13	Erik Ostrowski	www.avrobio.com

AVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company’s pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trials for the treatment of Fabry disease; and AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease.

AVROBIO, Inc. Fundamentals Summary

How do AVROBIO's earnings and revenue compare to its market cap?
AVRO fundamental statistics
Market cap	US$63.75m
Earnings (TTM)	US$30.31m
Revenue (TTM)	n/a

24.9x

P/E Ratio

0.0x

P/S Ratio

Is AVRO overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AVRO income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	-US$30.31m
Earnings	US$30.31m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	0.68
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did AVRO perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/06/20 00:45
End of Day Share Price	2024/06/20 00:00
Earnings	2024/03/31
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

AVROBIO, Inc. is covered by 15 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Yun Zhong	Brean Capital Historical (Janney Montgomery)
Yun Zhong	BTIG
Whitney Ijem	Guggenheim Securities, LLC

This company is no longer active

AVROBIO (AVRO) Stock Overview

Rewards

Risk Analysis

AVROBIO, Inc. Competitors

Spero Therapeutics

Eagle Pharmaceuticals

Protalix BioTherapeutics

CytomX Therapeutics

Price History & Performance

Recent News & Updates

Tectonic Therapeutic, Inc. completed the acquisition of AVROBIO, Inc. (NasdaqGS:AVRO) from a group of shareholders in a reverse merger transaction.

Investor sentiment improves as stock rises 1,043%

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

New minor risk - Shareholder dilution

AVROBIO, Inc. (NasdaqGS:AVRO) entered into an agreement to acquire Tectonic Therapeutic, Inc.

Recent updates

Tectonic Therapeutic, Inc. completed the acquisition of AVROBIO, Inc. (NasdaqGS:AVRO) from a group of shareholders in a reverse merger transaction.

Investor sentiment improves as stock rises 1,043%

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

New minor risk - Shareholder dilution

AVROBIO, Inc. (NasdaqGS:AVRO) entered into an agreement to acquire Tectonic Therapeutic, Inc.

No longer forecast to breakeven

Price target decreased by 16% to US$3.00

New major risk - Revenue and earnings growth

Chief Business Officer notifies of intention to sell stock

Novartis Pharma AG and Novartis Pharmaceuticals Corporation entered into an Asset Purchase Agreement to acquire Cystinosis Gene Therapy Program from AVROBIO, Inc. (NasdaqGS:AVRO) for $87.5 million.

Price target decreased by 8.5% to US$3.58

Co- Founder exercised options to buy US$104k worth of stock.

AVROBIO, Inc. Announces New Positive Clinical Data and Outlines Clinical Development Plan Following Regulatory Discussions for Its Gaucher Disease Gene Therapy

Price target decreased to US$4.14

Insufficient new directors

Avrobio Receives Rare Pediatric Disease Designation from the U.S. FDA for First-In-Class Gene Therapy for Gaucher Disease

AVROBIO, Inc. Announces Completion of Patient Dosing in First Gene Therapy Clinical Trial for Cystinosis

AVROBIO, Inc. announces U.K. Medicines and Healthcare products Regulatory Agency grant an Innovation Passport under the Innovative Licensing and Access Pathway

Avrobio rises as gene therapy for Gaucher disease gets ILAP designation in UK

AVROBIO, Inc. Reports Favorable Data on Use of Combined State-Of-The-Art in Vitro Cell-Based Assays to Identify Potential Genotoxicity Risk of Integrating Vectors During Preclinical Development

AVROBIO Receives Written Notice from The Nasdaq Stock Market Regarding Minimum Bid Price Requirement

AVROBIO, Inc. Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for First Gene Therapy in Development for Cystinosis

Avrobio stock rises as kidney disease gene therapy gets FDA rare pediatric disease status

AVROBIO Inc. Announces Neuronopathic Mucopolysaccharidosis Type II or Hunter Syndrome Clinical Trial Application Accepted by U.K. Regulatory Agency to Initiate Pediatric Phase 1/2 Gene Therapy Trial

AVROBIO granted FDA’s orphan drug designation for metabolic disorder therapy

AVROBIO, Inc.(NasdaqGS:AVRO) dropped from Russell 2500 Index

AVROBIO, Inc. Announces Preclinical Data Demonstrating the Efficacy and Safety of AVR-RD-03 Gene Therapy in A Mouse Model of Infantile Onset Pompe Disease

Avrobio Reports Positive Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis, Including New Interim Data on Neurocognitive Measures

Price target decreased to US$6.29

Insufficient new directors

AVROBIO, Inc. Reports Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis

Insufficient new directors

Insufficient new directors

AVROBIO, Inc. Announces the Appointment of Sean O’Bryan as Chief Regulatory Officer

AVROBIO, Inc. Announces New Data from Phase 2 Fab-Gt Clinical Trial Show Variable Engraftment

AVROBIO, Inc Presents Clinician Experience with FAB-GT Clinical Trial and Updated Safety Data for Investigational Gene Therapies in Fabry Disease and Gaucher Disease Type 1

Price target decreased to US$22.88

Price target increased to US$25.14

Here's Why We're Watching AVROBIO's (NASDAQ:AVRO) Cash Burn Situation

We're Keeping An Eye On AVROBIO's (NASDAQ:AVRO) Cash Burn Rate

AVROBIO, Inc.(NasdaqGS:AVRO) dropped from Russell 2500 Growth Index

AVROBIO, Inc. Provides Regulatory Update on Investigational AVR-RD-01 for Fabry Disease

AVROBIO, Inc. Announces Two Oral Presentations and Two Posters Featuring Data from Its Pipeline of Lysosomal Disorder Gene Therapy

Here's Why We're Not Too Worried About AVROBIO's (NASDAQ:AVRO) Cash Burn Situation

Price target lowered to US$34.50

AVROBIO, Inc. Receives Orphan Drug Designation from the European Commission for AVR-RD-04, an Investigational Gene Therapy for Cystinosis

AVROBIO, Inc. Announces 100% Kidney Substrate Reduction at 12 Months Post-Gene Therapy in First Patient Dosed with plato Gene Therapy Platform in Fabry Disease Phase 2 Trial

New 90-day high: US$17.11

Avrobio Appoints Diana M. Escolar as Chief Medical Officer

AVROBIO, Inc. Appoints Diana M. Escolar as Chief Medical Officer

We Think AVROBIO (NASDAQ:AVRO) Can Afford To Drive Business Growth

AVROBIO, Inc. Avrobio Announces New Positive Clinical Data and Preclinical Data, as Well as Expanded Leading Lysosomal Disorder Gene Therapy Pipeline

Price target raised to US$38.50

Avrobio, Inc. Enters into Agreement with University of Manchester, England

Avrobio, Inc. Receives Orphan Drug Designation from the European Medicines Agency for Avr-Rd-02, an Investigational Gene Therapy for Gaucher Disease

New 90-day low: US$15.00

Shareholder Returns

Price Volatility

About the Company

AVROBIO, Inc. Fundamentals Summary

Earnings & Revenue